Published in J Neurol on October 01, 1991
Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry (1997) 2.52
Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients. J Neurol Neurosurg Psychiatry (1996) 0.96
Antiglycolipid antibodies in peripheral neuropathy: fact or fiction? J Neurol Neurosurg Psychiatry (1994) 0.90
IgG monoclonal paraproteinaemia and peripheral neuropathy. J Neurol Neurosurg Psychiatry (1993) 0.84
Paraproteinemic neuropathy: a practical review. BMC Neurol (2016) 0.82
Multifocal motor neuropathy, multifocal acquired demyelinating sensory and motor neuropathy, and other chronic acquired demyelinating polyneuropathy variants. Neurol Clin (2013) 0.80
Systematic reviews of treatment for inflammatory demyelinating neuropathy. J Anat (2002) 0.79
Successful treatment of IgM paraproteinaemic neuropathy with fludarabine. J Neurol Neurosurg Psychiatry (1999) 0.79
Myelin protein zero is naturally processed in the B cells of monoclonal gammopathy of undetermined significance of immunoglobulin M isotype: aberrant triggering of a patient's T cells. Haematologica (2009) 0.78
Axonal neuropathy associated with monoclonal gammopathy of undetermined significance. J Neurol Neurosurg Psychiatry (1997) 0.77
Comparison of monoclonal gammopathy of undetermined significance-associated neuropathy and chronic inflammatory demyelinating polyneuropathy patients. J Neurol (2014) 0.76
Analyzing Relationship Between Monoclonal Gammopathy of Undetermined Significance (MGUS) with Different Types of Neuropathy: An Observational Study. Indian J Hematol Blood Transfus (2015) 0.75
Are neurological complications of monoclonal gammopathy of undetermined significance underestimated? Oncotarget (2016) 0.75
Advances in the Treatment of Paraproteinemic Neuropathy. Curr Treat Options Neurol (2017) 0.75
Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature (1997) 15.73
Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med (1995) 5.73
Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain (2009) 5.03
A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care (1994) 5.02
Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet (2004) 4.85
The clinical features of hereditary motor and sensory neuropathy types I and II. Brain (1980) 4.79
Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet (1997) 4.43
Changes due to age in internodal length in the sural nerve in man. J Neurol Neurosurg Psychiatry (1966) 3.96
"Friendly fire" in medicine: hormones, homografts, and Creutzfeldt-Jakob disease. Lancet (1992) 3.74
Controlled trial prednisolone in acute polyneuropathy. Lancet (1978) 3.71
Geographical distribution of variant CJD in the UK (excluding Northern Ireland). Lancet (1999) 3.39
Predicting susceptibility and incubation time of human-to-human transmission of vCJD. Lancet Neurol (2006) 3.29
Galactocerebroside is a specific cell-surface antigenic marker for oligodendrocytes in culture. Nature (1978) 3.29
Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology (2000) 3.23
Shoulder disorders in the elderly: a community survey. Arthritis Rheum (1991) 3.21
Predicting the CJD epidemic in humans. Nature (1997) 3.04
Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology (2000) 3.03
Creutzfeldt-Jakob disease and blood transfusion. Lancet (1993) 2.97
The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease. Lancet (2000) 2.92
The impact of long-term warfarin therapy on quality of life. Evidence from a randomized trial. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. Arch Intern Med (1991) 2.92
Molecular assessment of the potential transmissibilities of BSE and scrapie to humans. Nature (1997) 2.80
Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study. Circulation (1990) 2.74
A retrospective study of Creutzfeldt-Jakob disease in England and Wales 1970-79. I: Clinical features. J Neurol Neurosurg Psychiatry (1984) 2.68
Manual motor performance in a deafferented man. Brain (1982) 2.63
A prospective study of acute idiopathic neuropathy. II. Antecedent events. J Neurol Neurosurg Psychiatry (1988) 2.63
Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: background, evolution, and current concerns. Emerg Infect Dis (2001) 2.62
A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value. J Neurol Neurosurg Psychiatry (1988) 2.56
Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. Brain (2006) 2.54
Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry (1997) 2.52
N-myc downstream-regulated gene 1 is mutated in hereditary motor and sensory neuropathy-Lom. Am J Hum Genet (2000) 2.47
Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol (1998) 2.47
Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford) (2004) 2.37
Genetic aspects of hereditary motor and sensory neuropathy (types I and II). J Med Genet (1980) 2.36
The role of cerebrospinal fluid 14-3-3 and other proteins in the diagnosis of sporadic Creutzfeldt-Jakob disease in the UK: a 10-year review. J Neurol Neurosurg Psychiatry (2010) 2.29
Genetic and biochemical evidence of a Campylobacter jejuni capsular polysaccharide that accounts for Penner serotype specificity. Mol Microbiol (2000) 2.28
Ultrastructural studies of the dying-back process. II. The sequestration and removal by Schwann cells and oligodendrocytes of organelles from normal and diseases axons. J Neurocytol (1974) 2.27
Recurrent and chronic relapsing Guillain-Barré polyneuritis. Brain (1969) 2.26
Immunogenicity of human amniotic epithelial cells after transplantation into volunteers. Lancet (1981) 2.23
Evidence for case-to-case transmission of Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry (1982) 2.15
Nosocomial multiply resistant Klebsiella pneumoniae: epidemiology of an outbreak of apparent index case origin. Antimicrob Agents Chemother (1979) 2.13
Pathogenesis of Guillain-Barré syndrome. J Neuroimmunol (1999) 2.08
Epidemiological study of Guillain-Barré syndrome in south east England. J Neurol Neurosurg Psychiatry (1998) 2.07
The psychometric properties of clinical rating scales used in multiple sclerosis. Brain (1999) 2.06
Deaths from variant Creutzfeldt-Jakob disease. Lancet (1999) 2.04
The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler (1999) 2.02
Imaging in transient regional osteoporosis. Br J Rheumatol (1997) 2.01
Stroke prevention in nonvalvular atrial fibrillation. Ann Intern Med (1991) 2.01
Geographical distribution of variant Creutzfeldt-Jakob disease in Great Britain, 1994-2000. Lancet (2001) 1.97
Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Brain (2004) 1.96
Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. Neurology (2005) 1.88
X-linked scapuloperoneal syndrome. J Neurol Neurosurg Psychiatry (1972) 1.87
Relapsing polychondritis. Three cases with a clinico-pathological study and literature review. Q J Med (1972) 1.87
Creutzfeldt-Jakob disease in England and Wales, 1980-1984: a case-control study of potential risk factors. J Neurol Neurosurg Psychiatry (1988) 1.87
Involvement of the central nervous system in chronic inflammatory demyelinating polyneuropathy: a clinical, electrophysiological and magnetic resonance imaging study. J Neurol Neurosurg Psychiatry (1990) 1.87
Peripheral nerve structure and function in experimental diabetes. J Neurol Sci (1974) 1.86
Phase variation of a beta-1,3 galactosyltransferase involved in generation of the ganglioside GM1-like lipo-oligosaccharide of Campylobacter jejuni. Mol Microbiol (2000) 1.85
Detection of variant Creutzfeldt-Jakob disease infectivity in extraneural tissues. Lancet (2001) 1.84
Overview of azathioprine treatment in multiple sclerosis. Lancet (1991) 1.83
The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology (1999) 1.82
The in vivo and ultrastructural effects of injection of lysophosphatidyl choline into myelinated peripheral nerve fibres of the adult mouse. J Cell Sci (1971) 1.82
Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res (2000) 1.80
Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study. Vox Sang (2006) 1.76
Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology (2001) 1.74
Hypertrophic neuropathy. Q J Med (1967) 1.72
The natural history of acute painful neuropathy in diabetes mellitus. J Neurol Neurosurg Psychiatry (1983) 1.72
New variant Creutzfeldt-Jakob disease: neurological features and diagnostic tests. Lancet (1997) 1.70
The examination of isolated nerve fibres by light and electron microscopy, with observations on demyelination proximal to neuromas. Acta Neuropathol (1970) 1.70
Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Hum Mol Genet (2000) 1.70
Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med (2001) 1.69
Amount of research interest in rare and common neurological conditions: bibliometric study. BMJ (2001) 1.68
Antibodies to gangliosides in Guillain-Barré syndrome: specificity and relationship to clinical features. Q J Med (1993) 1.67
Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital. Antimicrob Agents Chemother (1991) 1.67
Sural nerve biopsies in Guillain-Barre syndrome: axonal degeneration and macrophage-associated demyelination and absence of cytomegalovirus genome. Muscle Nerve (1992) 1.67
Neuroacanthocytosis. A clinical, haematological and pathological study of 19 cases. Brain (1991) 1.67
The morphological basis for alterations in nerve conduction in peripheral neuropathy. Proc R Soc Med (1971) 1.66
Multiple N-acetyl neuraminic acid synthetase (neuB) genes in Campylobacter jejuni: identification and characterization of the gene involved in sialylation of lipo-oligosaccharide. Mol Microbiol (2000) 1.66
Hereditary demyelinating neuropathy of infancy. A genetically complex syndrome. Brain (1997) 1.65
Sural nerve pathology in diabetic patients with minimal but progressive neuropathy. Diabetologia (2005) 1.64
The chronic fatigue syndrome: what do we know? BMJ (1993) 1.63
The phenotypic manifestations of chromosome 17p11.2 duplication. Brain (1997) 1.63
A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy. Brain (2004) 1.62
Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry (2000) 1.62
Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int (2000) 1.62
MRI lesion profiles in sporadic Creutzfeldt-Jakob disease. Neurology (2009) 1.61
Gene mapping in Gypsies identifies a novel demyelinating neuropathy on chromosome 8q24. Nat Genet (1996) 1.61
Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa. Br Med J (1971) 1.60
Anti-ganglioside GM1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection. Ann Neurol (1995) 1.60
Case-control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993-95. European Union (EU) Collaborative Study Group of Creutzfeldt-Jakob disease (CJD). Lancet (1998) 1.60
Epineurial microvasculitis in proximal diabetic neuropathy. J Neurol (1998) 1.60
Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. Am J Med (1990) 1.57
Partial deficiency of the C-terminal-domain phosphatase of RNA polymerase II is associated with congenital cataracts facial dysmorphism neuropathy syndrome. Nat Genet (2003) 1.57
Trigeminal sensory neuropathy. A study of 22 cases. Brain (1987) 1.56
Spinocerebellar degeneration secondary to chronic intestinal malabsorption: a vitamin E deficiency syndrome. Ann Neurol (1982) 1.56